Substance P: binding properties and studies on cellular responses in guinea pig macrophages.
The neuropeptide Substance P (SP) has been recognized to modulate functional activities of inflammatory cells. We have previously shown that it mediates macrophage activation. In this study we examined binding characteristics of SP and searched for additional evidence of heightened metabolic activity of guinea pig peritoneal macrophages upon challenge with this peptide. Radioligand studies indicated the existence of a homogeneous class of specific binding sites with high affinity for SP on macrophages. Scatchard analysis yielded an apparent KD of 1.9 +/- 0.4 X 10(-8) M (range: 1.4 to 2.4 X 10(-8) M), which was confirmed by kinetic studies. Binding was dose related, saturable, reversible, and could be inhibited by the SP antagonist (D-Pro2,D-Phe7,D-Trp9)-SP. Examination of peptide structural requirements revealed that both the COOH- and NH2-terminus contribute to receptor-ligand interaction. Other members of the tachykinin group of peptides were devoid of stimulatory action on macrophages. Cellular responses after engagement of the receptor sites by SP included downregulation of the membrane-associated enzyme 5'-nucleotidase and stimulation of synthesis and release of arachidonic acid metabolites, as well as of the lysosomal enzyme ADGase. These actions were specific as evidenced by immunoabsorption experiments. Our findings demonstrate that macrophage activation afforded by SP is effected through a receptor-mediated mechanism. Liberation of proinflammatory and immunomodulating substances in response to SP may be relevant to the pathogenesis of neuroinflammatory disease.
H P
HP
Hartung
K
K
Wolters
K V
KV
Toyka
D015720:5'-Nucleotidase; D000118:Acetylglucosaminidase / Q000378:metabolism*; D000595:Amino Acid Sequence; D000818:Animals; D002396:Catechols / Q000494:pharmacology; D005959:Glucosidases / Q000378:metabolism; D006168:Guinea Pigs; D006596:Hexosaminidases / Q000378:metabolism*; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D008247:Lysosomes / Q000201:enzymology; D008262:Macrophage Activation; D008264:Macrophages / Q000502:physiology*; D009637:Masoprocol; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009708:Nucleotidases / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D018040:Receptors, Neurokinin-1; D017981:Receptors, Neurotransmitter / Q000502:physiology*; D013189:SRS-A / Q000378:metabolism; D013329:Structure-Activity Relationship; D013373:Substance P / Q000378:metabolism*; D015320:Tachykinins; D013929:Thromboxane B2 / Q000378:metabolism
D002396:Catechols; D009419:Nerve Tissue Proteins; D011453:Prostaglandins; D018040:Receptors, Neurokinin-1; D017981:Receptors, Neurotransmitter; D013189:SRS-A; D015320:Tachykinins; D013373:Substance P; D013929:Thromboxane B2; D009637:Masoprocol; D009708:Nucleotidases; D015720:5'-Nucleotidase; D005959:Glucosidases; D006596:Hexosaminidases; D000118:Acetylglucosaminidase; D007213:Indomethacin